Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 60 Breast Neoplasms 21 Neoplasms 19 Fallopian Tube Neoplasms 16 Prostatic Neoplasms 15 Neoplasm Metastasis 9 Pancreatic Neoplasms 8 Endometrial Neoplasms 8 Glioblastoma 7 Triple Negative Breast Neoplasms 6 Lung Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Small Cell Lung Carcinoma 4 Glioma 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Mesothelioma 3 Melanoma 3 Head and Neck Neoplasms 3 Cystadenocarcinoma, Serous 3 Cholangiocarcinoma 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Urogenital Neoplasms 2 Stomach Neoplasms 2 Solid Tumor 2 Sarcoma 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Diseases 2 Mesothelioma, Malignant 2

Interventions

Gemcitabine 4 Cisplatin 4 pembrolizumab 3 Carboplatin 3 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Urothelial Cancer × niraparib × Clear all

NCT03425201 2024-12-31

NICARAGUA

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1/2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡